Cargando…
Response of prostate cancer to addition of dutasteride after progression on abiraterone
Autores principales: | Lian, Jian-Po, Gao, Yuan-Yuan, Tang, Jing-Jie, Chen, Xi, Liu, Ying, Wu, Deng-Long, Li, Zhen-Fei, Huang, Sheng-Song |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991817/ https://www.ncbi.nlm.nih.gov/pubmed/32896838 http://dx.doi.org/10.4103/aja.aja_45_20 |
Ejemplares similares
-
Mesotherapy with Dutasteride in the Treatment of Androgenetic Alopecia
por: Saceda-Corralo, David, et al.
Publicado: (2017) -
The clinical efficacy and limitations of dutasteride-regulated abiraterone metabolism in abiraterone-resistant patients: a prospective single-arm clinical trial in Chinese patients
por: Liu, Ying, et al.
Publicado: (2022) -
Low cost abiraterone
por: Barreiro, Diego Martin, et al.
Publicado: (2015) -
Bone Health Risks Associated with Finasteride and Dutasteride Long-Term Use
por: Sirufo, Maria Maddalena, et al.
Publicado: (2021) -
Quadriplegia secondary to abiraterone-induced severe hypokalemia
por: Rajvanshi, Jignesh B., et al.
Publicado: (2019)